PROTECT PHARMACEUTICAL Corp (PRTT) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
95 MERRICK WAY, THIRD FLOOR CORAL GABLES, FL 33143 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | 12/31/2016 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 100 | ||||||||
| Cash and cash equivalents | 100 | ||||||||
| Total current assets: | 100 | ||||||||
| Noncurrent Assets | |||||||||
| TOTAL ASSETS: | 100 | ||||||||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 950 | 950 | 950 | 950 | 950 | 9,950 | |||
| Interest and dividends payable | 9,937 | 6,211 | 2,485 | ||||||
| Other undisclosed accounts payable and accrued liabilities | (8,987) | (5,261) | (1,535) | 950 | 950 | 9,950 | |||
| Due to related parties | 35,380 | 35,280 | 35,280 | 35,280 | 35,280 | 10,880 | |||
| Other undisclosed current liabilities | 9,937 | 6,211 | 2,485 | ||||||
| Total current liabilities: | 46,267 | 42,441 | 38,715 | 36,230 | 36,230 | 20,830 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 101,000 | 101,000 | 100,833 | 100,333 | |||||
| Long-term debt, excluding current maturities | 101,000 | 101,000 | 100,833 | 100,333 | |||||
| Total noncurrent liabilities: | 101,000 | 101,000 | 100,833 | 100,333 | |||||
| Total liabilities: | 147,267 | 143,441 | 139,548 | 136,563 | 36,230 | 20,830 | |||
| Equity | |||||||||
| Equity, attributable to parent | (147,167) | (143,441) | (139,548) | (136,563) | (36,230) | (20,830) | |||
| Common stock | 5,557 | 5,557 | 5,557 | 5,557 | 5,557 | 5,557 | |||
| Additional paid in capital | 9,365,612 | 9,365,612 | 9,365,612 | 9,365,612 | 9,365,612 | 9,365,612 | |||
| Accumulated deficit | (9,518,336) | (9,514,610) | (9,510,717) | (9,507,732) | (9,407,399) | (9,391,999) | |||
| Total equity: | (147,167) | (143,441) | (139,548) | (136,563) | (36,230) | (20,830) | |||
| TOTAL LIABILITIES AND EQUITY: | 100 | ||||||||
Income Statement (P&L) (USD)Annual | Quarterly
| 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | 12/31/2016 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Other undisclosed income before gain (loss) on sale of properties | 21,292 | |||||||
| Operating expenses | (100,000) | (200) | (45) | |||||
| Other undisclosed operating income (loss) | (15,200) | 4,500 | ||||||
| Operating income (loss): | (100,000) | (15,400) | 4,455 | |||||
| Interest and debt expense | (3,726) | (3,893) | (2,985) | (333) | ||||
| Income (loss) from continuing operations: | (3,726) | (3,893) | (2,985) | (100,333) | (15,400) | 4,455 | ||
| Income (loss) before gain (loss) on sale of properties: | (3,726) | (3,893) | (2,985) | (100,333) | (15,400) | 25,747 | ||
| Other undisclosed net loss | (46,162) | |||||||
| Net loss available to common stockholders, diluted: | (3,726) | (3,893) | (2,985) | (100,333) | (15,400) | (20,415) | ||
Comprehensive Income (USD)Annual | Quarterly
| 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | 12/31/2016 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (3,726) | (3,893) | (2,985) | (100,333) | (15,400) | (20,415) | ||
| Comprehensive loss, net of tax, attributable to parent: | (3,726) | (3,893) | (2,985) | (100,333) | (15,400) | (20,415) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.